Company Overview VERASTEM, INC.

  (NASDAQ Global Market: VSTM)

117 Kendrick St Ste 500, NEEDHAM, Massachusetts - Sector (ICB) Pharmaceuticals & CUSIP 92337C104 SIC Code 8731 Employees 69
MA  02494-2730, UNITED STATES Biotechnology

+1 781 292-4200 http://www.verastem.com Subsector Biotechnology SEDOL B4Z1Y92 Auditor Ernst & Young Fiscal Year 12/31/17
(ICB) End :

Financial Summary Business Description

  Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and
Last Twelve 12/31/17  12/31/18  12/31/19 
Months as of  (A) (E) (E) developing drugs to improve outcomes for patients with cancer. The Company operates in the
06/30/18 segment of developing drugs for the treatment of cancer. The Company's advanced product
candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal
Sales (MM) 10 0 7 45
Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor
Growth - 0 - 526.1 tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in
Gross Profit 9 (1) - - cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally
(MM) available small molecule compounds designed to inhibit FAK signaling. The Company's
VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K
Margin 89.4 - 85.0 92.5
signaling. The Company is engaged in running clinical trials in cancers where there are
EBITDA (MM) (78) (67) - - limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced
Margin (782.9) - - - cancers.

EBIT (MM) (79) (67) (105) (76)

Margin (793.4) - (1465.2) (169.0) Key Ratios
Net Income (MM) (81) (68) (106) (79)  
Last Twelve 12/31/17  12/31/18  12/31/19 
Margin (807.8) - (1483.1) (177.2) Months as of  (A) (E) (E)
06/30/18 *
EPS (1.75) (1.76) (1.64) (1.08)
Enterprise 58.9 - 82.5 13.2
Growth 40.9 79.1 (6.8) (34.5)
Value/Sales
Free Cash Flow (75) (62) - -
Enterprise NEG NEG - -
Currency:  USD Source: Worldscope, IBES Value/EBITDA
Enterprise NEG NEG NEG NEG
Value/EBIT
Market Data
Total 0.0 0.2 - -
Price (10:33 AM*) 10.26 Change    0.30(3.00%) Debt/Enterprise
Value
Volume 1,254,436 52 Wk Range 10.03 - 2.77
Total Debt/EBITDA NEG NEG - -
Consolidated Market 733  (MM) Dividend Yield 0.00%
Cap** EBITDA/Interest (54.6) (119.3) - -
Expense
1 Year Total Return 154.08% Beta (Historical) 2.65
EBITDA-Capital (55.1) (119.3) - -
Float as % of Shares 94%    
Expenditures/Intere
Outstanding
st Expense
*Time stamp based on security's exchange (US),  USD **Prices as of  08/31/18,  USD
EBIT/Interest (55.3) (120.3) (73.0) (52.7)
Expense

Price and Volume: 1 Year Price/Earnings NEG NEG NEG NEG

PEG - - 0.9 0.3
Price/Sales 73.3 - 102.6 16.4
Price/ NEG NEG NEG NEG
Cash Flow
Price/Book Value 5.8 2.7 8.0 21.6
Return On Assets (68.0) (77.8) (103.3) (93.2)
Return On Equity (92.3) (104.3) (185.5) 67.3
Return On Invested (105.2) (93.1) - -
Capital
*EV and Price Multiples calculated using price as of  08/31/18 Source: Worldscope, IBES

Analyst Rating

Source: First Call

Earnings Estimate Revisions

Source: First Call

Earnings Estimate Forecasts

Source: First Call

 Capital Structure Ownership Breakdown
Consolidated Market Cap* 733 Total Shareholders Equity 127 Investor Type Investors % Shares Outstanding
- Cash and Short Term 169 Total Capital 150
Investment Managers 176 43.11
+ Short Term Debt 1 Debt to Equity 19.63
Brokerage Firms 16 1.06
+ Long Term Debt 24 Debt to Capital 16.41
Strategic Entities 9 6.29
+ Preferred Stock 0    
Holding Companies 0 0.00
+ Minority Interest 0   
Corporations 3 5.76
= Enterprise Value 589    

*Price as of  08/31/18  , USD  in millions    Date of filing 06/30/18  

Individuals 6 0.53
Government Agency 0 0.00
Total - All Holders 201 50.45
Directors
Name Title
Top 5 Shareholders
Michael G. Kauffman Lead Independent Director
Investor Name % Shares Current Position Value Position Date
Eric K. Rowinsky Director
Outstanding ($MM)
Brian M. Stuglik Director
Consonance Capital 9.74 7,166,666 49.31 06/30/18
Timothy Joseph Barberich Independent Director Management LP
Alison  Lawton Independent Director Fidelity Management & 5.51 4,058,097 27.92 06/30/18
S. Louise  Phanstiel Independent Director Research Company

Bruce J. Wendel Independent Director BlackRock Institutional Trust 4.46 3,279,050 22.56 06/30/18
Company, N.A.
The Vanguard Group, Inc. 3.53 2,598,007 17.87 06/30/18
Officers BVF Partners L.P. 3.05 2,242,353 15.43 06/30/18

Name Title

Robert  Forrester President, Chief Executive Officer Upcoming Events

Robert E. Gagnon Chief Financial Officer Event Event Name Date/Time
Daniel W. Paterson Chief Operating Officer
Q3 2018 Verastem Inc Earnings Release 11/05/18 / AMC-ET
Joseph M. Lobacki Executive Vice President and Chief
Commercial Officer Time displayed in Eastern Daylight Time
Joseph  Chiapponi Vice President - Finance
Monica  Kleinman Vice President, General Counsel Past Events
Michael  Ferraresso Vice President - Commercial Operations
Event Event Name Date/Time
Lori A. Kunkel Clinical and Scientific Advisory Board
Q2 2018 Verastem Inc Earnings Release 08/08/18 / AMC-ET
Hagop  Youssoufian Head - Hematology and Oncology
Development Q1 2018 Verastem Inc Earnings Release 05/03/18 / NTS
Q4 2017 Verastem Inc Earnings Release 03/13/18 / BMO

Time displayed in Eastern Daylight Time

 Business Segment  Mergers & Acquisitions

Data Not Available. Data Not Available.

Geographic Segment as of  12/31/17 Equity Issues

Issue Date Issuer Proceeds Amount Issue Type Security Type
+ Overallotment
Sold All
Market(mil)

05/16/18 Verastem Inc 40.3 Follow-On Common Shares

01/22/15 Verastem Inc 54.2 Follow-On Common Shares
07/17/13 Verastem Inc 63.8 Follow-On Common Shares
*Source: Thomson Financial

Bonds Issues

Data Not Available.

Key Competitors Loans Issues

Biotechnology Data Not Available.

Name Consolidated Sales EBITDA Enterprise
Market Cap - Last Twelve Margin - Last Value/EBIT
- Current (MM) Months (MM) Twelve DA
Months - FY1
News

Stemline Therapeutics Inc 529.67 1 -9396.3 - Date Headline Source

Celgene Corporation 66,432.56 14,165 39.9 9.1 08/30/18 04:52 PM Verastem, Inc. SEC Filings files SCF
Form -- 4
Oncomed Pharmaceuticals 88.55 40 - -
Inc 08/30/18 04:44 PM Verastem, Inc. -- 3 SCF
Sumitomo Dainippon 7,792.55 4,263 20.9 0.1 08/29/18 05:26 PM Verastem, Inc. Files -- 8-K SCF
Pharma Co Ltd
08/29/18 04:07 PM BRIEF-Verastem Oncology Reuters
Astellas Pharma 34,087.15 11,943 23.0 0.1 Appoints Robert Gagnon As CFO
Incorporated
08/29/18 04:05 PM VERASTEM INC - Reuters
Glaxosmithkline Plc 101,269.7 40,550 18.0 9.7 APPOINTMENT OF ROBERT E.
GAGNON AS CHIEF FINANCIAL
Sanofi S.a. 112,652.31 42,264 23.3 12.2
OFFICER, EFFECTIVE AUGUST
Verastem Inc 732.98 10 -782.9 - 28, 2018
Currency: USD Defined by Thomson Reuters proprietary algorithm 08/29/18 04:05 PM VERASTEM INC <VSTM.O> Reuters
Source: Worldscope, IBES SAYS ROBERT E. GAGNON
APPOINTED CFO
08/29/18 04:05 PM VERASTEM ONCOLOGY Reuters
APPOINTS ROBERT E.
GAGNON AS CHIEF FINANCIAL
OFFICER
08/29/18 04:05 PM Verastem Oncology Appoints Business Wire
Robert E. Gagnon as Chief
Financial Officer
08/15/18 09:05 PM Wall Street expects a loss of Thomson Reuters Earnings News
$0.44 per share for Verastem's
(VSTM) third quarter
08/10/18 04:09 AM A loss of $0.40 per share Thomson Reuters Earnings News
anticipated for Verastem's
(VSTM) third quarter
Time displayed in Eastern Daylight Time
 Embargoed Research Significant Developments
Date Title Contributor Date Headline Topic

09/04/18 Verastem, Inc. CFRA Quantitative Report 08/29/18 Verastem Oncology Appoints Robert Gagnon As CFO Officer Changes
04:05 PM
09/03/18 Verastem, Inc. - Company Report Infinata
Aug 29 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY APPOINTS ROBERT E.
09/02/18 Verastem Oncology - Cortellis Clarivate Analytics
GAGNON AS CHIEF FINANCIAL OFFICER.SAYS ROBERT E. GAGNON APPOINTED
Company and Pipeline Overview
CFO.APPOINTMENT OF ROBERT E. GAGNON AS CHIEF FINANCIAL OFFICER, EFFECTIVE
Report
AUGUST 28, 2018.
09/02/18 Verastem Oncology - Cortellis Clarivate Analytics
08/08/18 Verastem Q2 Loss Per Share $0.30 Earnings
Company Detailed Pipeline Report
04:05 PM Announcements
08/29/18 ValuEngine Rating and Forecast ValuEngine, Inc.
Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY REPORTS SECOND QUARTER 2018 FINANCIAL
Report for VSTM
RESULTS.Q2 LOSS PER SHARE $0.30.Q2 EARNINGS PER SHARE VIEW $-0.34 -- THOMSON
REUTERS I/B/E/S.EXPECTS TO HAVE SUFFICIENT CASH AND CASH EQUIVALENTS TO FUND
OPERATIONS INTO 2020.AS OF JUNE 30, 2018, VERASTEM ONCOLOGY HAD CASH AND CASH
EQUIVALENTS OF $168.7 MILLION.
07/24/18 Verastem Files For Mixed Shelf Of Upto $200 Mln Debt Financing /
05:25 PM Related, Regulatory,
Equity Financing /
Related
July 24 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM INC FILES FOR MIXED SHELF OF UPTO
$200 MILLION - SEC FILING.
06/14/18 Verastem Oncology Announces $43.0 Million Offering Of Debt Financing /
04:03 PM Common Stock Related, Equity
Financing / Related,
Initial Public Offerings
June 14 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY ANNOUNCES $43.0 MILLION
OFFERING OF COMMON STOCK.VERASTEM INC - OFFERING OF COMMON STOCK STOCK AT A
PRICE OF $6.00 PER SHARE.
06/01/18 Verastem's Julie Feder Resigned As Chief Financial Officer Changes
08:29 AM Officer
June 1 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM SAYS ON MAY 30, 2018, JULIE FEDER
RESIGNED AS CHIEF FINANCIAL OFFICER OF VERASTEM - SEC FILING.VERASTEM INC -
EFFECTIVE MAY 31, DANIEL PATERSON CO'S COO WILL SERVE AS PRINCIPAL FINANCIAL
OFFICER ON AN INTERIM BASIS.
05/16/18 Verastem Oncology Announces Public Offering Of 7.78 Equity Financing /
09:29 AM Mln Common Shares Priced At $4.50per Share Related, Initial Public
Offerings
May 16 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY ANNOUNCES PRICING OF
PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.78 MILLION COMMON
SHARES PRICED AT $4.50PER SHARE.
05/15/18 Verastem Oncology Announces Public Offering Of Equity Financing /
04:01 PM Common Stock Related, Initial Public
Offerings
May 15 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY ANNOUNCES PUBLIC
OFFERING OF COMMON STOCK.VERASTEM INC - COMMENCED A REGISTERED
UNDERWRITTEN PUBLIC OFFERING OF $35 MILLION OF ITS SHARES OF COMMON
STOCK.VERASTEM INC - HAS COMMENCED A REGISTERED UNDERWRITTEN PUBLIC
OFFERING OF $35 MILLION OF ITS SHARES OF COMMON STOCK.
05/03/18 Verastem Oncology Reports Q1 Loss Per Share Of Earnings
04:05 PM $0.41 Announcements
May 3 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY REPORTS FIRST QUARTER
2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.41.Q1 EARNINGS PER SHARE VIEW $-0.39 --
THOMSON REUTERS I/B/E/S.EXPECTS TO HAVE SUFFICIENT CASH AND CASH EQUIVALENTS
TO FUND OPERATIONS INTO 2019.
04/09/18 FDA Accepts New Drug Application For Duvelisib And Products
03:00 AM Grants Priority Review
April 9 (Reuters) - Verastem Inc <VSTM.O>::FDA ACCEPTS NEW DRUG APPLICATION FOR
DUVELISIB AND GRANTS PRIORITY REVIEW.‍FDA TARGET ACTION DATE IS OCTOBER 5, 2018.
03/13/18 Verastem Reports Year-End 2017 Financial Results Other
07:00 AM Pre-Announcement
March 13 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM REPORTS YEAR-END 2017 FINANCIAL
RESULTS.VERASTEM - EXPECTS TO HAVE SUFFICIENT CASH, CASH EQUIVALENTS AND
INVESTMENTS TO FUND CURRENT OPERATING PLAN AND CAPEX REQUIREMENTS INTO H2
2018.
Time displayed in Eastern Daylight Time

Source Thomson Reuters Note Data is continuously updated and is therefore subject to change.

Copyright ©  2018 Thomson Reuters